- Home
- PCRX vs BULLW Comparison
PCRX vs BULLW Comparison
Compare PCRX & BULLW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- BULLW
- Stock Information
- Founded
- PCRX 2006
- BULLW N/A
- Country
- PCRX United States
- BULLW United States
- Employees
- PCRX N/A
- BULLW N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- BULLW Investment Bankers/Brokers/Service
- Sector
- PCRX Health Care
- BULLW Finance
- Exchange
- PCRX Nasdaq
- BULLW Nasdaq
- Market Cap
- PCRX 1.2B
- BULLW 987.5M
- IPO Year
- PCRX 2011
- BULLW N/A
- Fundamental
- Price
- PCRX $25.12
- BULLW $4.63
- Analyst Decision
- PCRX Buy
- BULLW
- Analyst Count
- PCRX 9
- BULLW 0
- Target Price
- PCRX $29.89
- BULLW N/A
- AVG Volume (30 Days)
- PCRX 782.0K
- BULLW N/A
- Earning Date
- PCRX 05-08-2025
- BULLW N/A
- Dividend Yield
- PCRX N/A
- BULLW N/A
- EPS Growth
- PCRX N/A
- BULLW N/A
- EPS
- PCRX N/A
- BULLW N/A
- Revenue
- PCRX $702,772,000.00
- BULLW N/A
- Revenue This Year
- PCRX $9.48
- BULLW N/A
- Revenue Next Year
- PCRX $11.31
- BULLW N/A
- P/E Ratio
- PCRX N/A
- BULLW N/A
- Revenue Growth
- PCRX 3.08
- BULLW N/A
- 52 Week Low
- PCRX $11.16
- BULLW N/A
- 52 Week High
- PCRX $31.67
- BULLW N/A
- Technical
- Relative Strength Index (RSI)
- PCRX 48.10
- BULLW N/A
- Support Level
- PCRX $25.08
- BULLW N/A
- Resistance Level
- PCRX $27.34
- BULLW N/A
- Average True Range (ATR)
- PCRX 1.16
- BULLW 0.00
- MACD
- PCRX -0.18
- BULLW 0.00
- Stochastic Oscillator
- PCRX 48.85
- BULLW 0.00
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.